Tech Company Financing Transactions
Iterion Therapeutics Funding Round
Iterion Therapeutics, operating out of Houston, scored $17 million in funding from Lumira Capital , Green Park & Golf Ventures and Sante Ventures.
Transaction Overview
Company Name
Announced On
2/17/2021
Transaction Type
Venture Equity
Amount
$17,000,000
Round
Series B
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
2450 West Holcombe Blvd.
Houston, TX 77021
USA
Houston, TX 77021
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Iterion Therapeutics is a clinical stage biotechnology company developing novel cancer therapeutics. The company's lead product, Tegavivint, is unique among nuclear ß-catenin inhibitors in that it binds to TBL1 (Transducin ßeta-like Protein One), a novel downstream target in the Wnt-signaling pathway.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Rahul Aras
Chief Medical Officer
Casey Cunningham
Chief Scientific Officer
Stephen Horrigan
VP - Operations
Rose Hernandez
VP - Regulatory Affairs
Gowri Sukumar
Browse more venture capital transactions:
Prev: 2/17/2021: CAGE Bio venture capital transaction
Next: 2/17/2021: Hemoshear venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to document every notable VC transaction. VC investment data records reported here are sourced from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs